Unity Biotechnology Stock EBITDA

UBX Stock

USD 1.42 0.02 1.43%

Unity Biotechnology fundamentals help investors to digest information that contributes to Unity Biotechnology's financial success or failures. It also enables traders to predict the movement of Unity Stock. The fundamental analysis module provides a way to measure Unity Biotechnology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Unity Biotechnology stock.

		Last Reported	Projected for Next Year
	EBITDA	-37.3 M	-39.1 M

EBITDA is likely to drop to about (39.1 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Unity Biotechnology Company EBITDA Analysis

Unity Biotechnology's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Unity Biotechnology EBITDA

(37.28 M)

Most of Unity Biotechnology's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Unity Biotechnology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Unity EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Unity Biotechnology is extremely important. It helps to project a fair market value of Unity Stock properly, considering its historical fundamentals such as EBITDA. Since Unity Biotechnology's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Unity Biotechnology's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Unity Biotechnology's interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Capital Surpluse	Total Liab	Total Current Assets	Common Stock	Property Plant Equipment	Net Receivables	Long Term Debt Total	Net Invested Capital	Net Working Capital	Deferred Long Term Liab	Capital Stock	Current Deferred Revenue	Short Term Debt	Long Term Debt	Short Long Term Debt
Total Assets		0.78	0.7	0.42	-0.17	0.83	0.29	-0.46	0.86	0.65	0.48	-0.88	0.43	0.77	0.83	0.22	0.35	0.4	0.12	0.25	-0.3
Total Stockholder Equity	0.78		0.78	0.75	-0.52	0.9	0.59	-0.91	0.55	0.76	0.53	-0.78	0.55	0.4	0.54	0.5	0.07	0.25	0.3	-0.18	0.13
Net Tangible Assets	0.7	0.78		0.67	-0.7	0.77	0.81	-0.67	0.46	0.67	0.55	-0.78	0.67	0.22	0.43	0.68	-0.04	0.27	0.44	-0.39	0.34
Net Debt	0.42	0.75	0.67		-0.88	0.45	0.86	-0.81	-0.01	0.67	0.74	-0.65	0.67	-0.16	-0.05	0.79	-0.18	0.47	0.77	-0.62	0.52
Retained Earnings	-0.17	-0.52	-0.7	-0.88		-0.29	-0.98	0.66	0.23	-0.53	-0.65	0.5	-0.7	0.45	0.28	-0.9	0.34	-0.28	-0.83	0.85	-0.75
Accounts Payable	0.83	0.9	0.77	0.45	-0.29		0.42	-0.74	0.73	0.72	0.39	-0.72	0.52	0.55	0.73	0.33	0.23	0.12	0.01	0.08	-0.09
Capital Surpluse	0.29	0.59	0.81	0.86	-0.98	0.42		-0.7	-0.07	0.62	0.67	-0.57	0.71	-0.34	-0.12	0.87	-0.25	0.26	0.75	-0.78	0.67
Total Liab	-0.46	-0.91	-0.67	-0.81	0.66	-0.74	-0.7		-0.22	-0.69	-0.46	0.53	-0.51	-0.01	-0.23	-0.57	0.13	-0.1	-0.38	0.44	-0.39
Total Current Assets	0.86	0.55	0.46	-0.01	0.23	0.73	-0.07	-0.22		0.33	0.02	-0.6	0.0	0.9	0.99	-0.22	0.32	0.01	-0.25	0.48	-0.48
Common Stock	0.65	0.76	0.67	0.67	-0.53	0.72	0.62	-0.69	0.33		0.86	-0.72	0.68	0.18	0.31	0.58	0.54	0.4	0.18	-0.06	-0.12
Property Plant Equipment	0.48	0.53	0.55	0.74	-0.65	0.39	0.67	-0.46	0.02	0.86		-0.67	0.8	-0.04	-0.02	0.73	0.42	0.7	0.45	-0.2	0.02
Net Receivables	-0.88	-0.78	-0.78	-0.65	0.5	-0.72	-0.57	0.53	-0.6	-0.72	-0.67		-0.64	-0.5	-0.53	-0.57	-0.22	-0.39	-0.46	0.11	0.01
Long Term Debt Total	0.43	0.55	0.67	0.67	-0.7	0.52	0.71	-0.51	0.0	0.68	0.8	-0.64		-0.07	-0.05	0.89	0.11	0.6	0.51	-0.33	0.28
Net Invested Capital	0.77	0.4	0.22	-0.16	0.45	0.55	-0.34	-0.01	0.9	0.18	-0.04	-0.5	-0.07		0.89	-0.31	0.42	0.11	-0.36	0.67	-0.63
Net Working Capital	0.83	0.54	0.43	-0.05	0.28	0.73	-0.12	-0.23	0.99	0.31	-0.02	-0.53	-0.05	0.89		-0.28	0.33	-0.01	-0.32	0.52	-0.5
Deferred Long Term Liab	0.22	0.5	0.68	0.79	-0.9	0.33	0.87	-0.57	-0.22	0.58	0.73	-0.57	0.89	-0.31	-0.28		-0.14	0.39	0.72	-0.68	0.6
Capital Stock	0.35	0.07	-0.04	-0.18	0.34	0.23	-0.25	0.13	0.32	0.54	0.42	-0.22	0.11	0.42	0.33	-0.14		0.24	-0.55	0.69	-0.84
Current Deferred Revenue	0.4	0.25	0.27	0.47	-0.28	0.12	0.26	-0.1	0.01	0.4	0.7	-0.39	0.6	0.11	-0.01	0.39	0.24		0.33	0.09	-0.08
Short Term Debt	0.12	0.3	0.44	0.77	-0.83	0.01	0.75	-0.38	-0.25	0.18	0.45	-0.46	0.51	-0.36	-0.32	0.72	-0.55	0.33		-0.8	0.73
Long Term Debt	0.25	-0.18	-0.39	-0.62	0.85	0.08	-0.78	0.44	0.48	-0.06	-0.2	0.11	-0.33	0.67	0.52	-0.68	0.69	0.09	-0.8		-0.95
Short Long Term Debt	-0.3	0.13	0.34	0.52	-0.75	-0.09	0.67	-0.39	-0.48	-0.12	0.02	0.01	0.28	-0.63	-0.5	0.6	-0.84	-0.08	0.73	-0.95

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Unity Biotechnology

Ebitda Over Time

Unity Ebitda

Ebitda

(39.15 Million)

Unity Biotechnology reported EBITDA of (37.28 Million) in 2023

According to the company disclosure, Unity Biotechnology reported earnings before interest,tax, depreciation and amortization of (37.28 Million). This is 104.25% lower than that of the Biotechnology sector and 137.23% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.96% higher than that of the company.

Unity EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Unity Biotechnology's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Unity Biotechnology could also be used in its relative valuation, which is a method of valuing Unity Biotechnology by comparing valuation metrics of similar companies.

Unity Biotechnology is currently under evaluation in ebitda category among its peers.

Unity Biotechnology Institutional Holders

Institutional Holdings refers to the ownership stake in Unity Biotechnology that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Unity Biotechnology's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Unity Biotechnology's value.

		Shares
Wells Fargo & Co	2024-06-30	43.4 K
Cercano Management Llc	2024-06-30	41.2 K
State Street Corp	2024-06-30	37.8 K
Bridgeway Capital Management, Llc	2024-06-30	25 K
Commonwealth Equity Services Inc	2024-06-30	24.6 K
Northern Trust Corp	2024-06-30	22.5 K
Susquehanna International Group, Llp	2024-06-30	17.8 K
Endowment Wealth Management, Inc.	2024-06-30	13.5 K
Advisor Group Holdings, Inc.	2024-06-30	13.1 K
Arch Venture Corp	2024-06-30	1 M
Alyeska Investment Group, L.p.	2024-06-30	920 K

Unity Fundamentals

	Return On Equity	-0.87
	Return On Asset	-0.23
	Current Valuation	11.26 M
	Shares Outstanding	16.85 M
	Shares Owned By Insiders	1.31 %
	Shares Owned By Institutions	20.52 %
	Number Of Shares Shorted	310.69 K
	Price To Book	1.19 X
	Price To Sales	6.54 X
	Gross Profit	(35.22 M)
	EBITDA	(37.28 M)
	Net Income	(39.86 M)
	Cash And Equivalents	64.51 M
	Cash Per Share	9.26 X
	Total Debt	26.99 M
	Debt To Equity	1.30 %
	Current Ratio	4.13 X
	Book Value Per Share	1.17 X
	Cash Flow From Operations	(38.65 M)
	Short Ratio	9.63 X
	Earnings Per Share	(1.92) X
	Target Price	6.67
	Number Of Employees	19
	Beta	0.83
	Market Capitalization	23.92 M
	Total Asset	65.69 M
	Retained Earnings	(484.35 M)
	Working Capital	38.77 M
	Net Asset	65.69 M

About Unity Biotechnology Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Unity Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unity Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unity Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

AVAV	AeroVironment
ELVN	Enliven Therapeutics
NFLX	Netflix

Additional Tools for Unity Stock Analysis

When running Unity Biotechnology's price analysis, check to measure Unity Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unity Biotechnology is operating at the current time. Most of Unity Biotechnology's value examination focuses on studying past and present price action to predict the probability of Unity Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unity Biotechnology's price. Additionally, you may evaluate how the addition of Unity Biotechnology to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC